Remedial Effect of Quadruple Therapy Based on Moxifloxacin and Bismuth on Eradication Failured of Helicobacter Pylori / 中山大学学报(医学科学版)

ABSTRACT

[Objective] To evaluate the efficacy and safety of quadruple therapy based on moxifloxacin and bismuth in the treatment of Helicobacter pylori eradication failure.[Methods] A prospective,randomized,comparative study was conducted in which 136 eligible patients were randomly divided into the extended quadruple group (66 patients,and the quadruplex therapies are Pectin bismuth 100 mg tid + lansoprazole 30 mg bid + amoxicillin 1000 mg bid + moxifloxacin 400 mg qd) and the classical quadruple group (70 patients,and the quadruple therapies are colloidal pectin bismuth 100 mg tid+ lansoprazole 30 mg bid +tetracycline tablet 750 mg Bid + metronidazole tablets 400 mg bid combination) and were under treatment for 14 days.One month after the treatment,endoscopy,rapid urease test,and 13-carbon/ 14-carbon urease breath test were used to evaluate the adverse effects and adherence of the drugs in the two groups respectively.[Results] In the extended quadruple group,among 60 patients who had completed the final treatment and follow-up survey,55 were successfully treated,with eradication rates of (83.3％,55/66)and 91.7％ (55/60) according to intention-to-treat (ITT) and Per-protocol (PP) respectively.In the classic quadruple group,64 patients completed the final treatment and follow-up survey.Among them,37 cases were successful,and the eradication rates according to ITT and PP remedy are 52.9％ (37/70) and 57.8％ (37/64) respectively.The difference was statistically significant (P ＜ 0.001).Adverse drug reactions and compliance monitoring showed no significant difference between the two groups (P ＞ 0.05).[Conclusion] The quadruple therapy based on moxifloxacin and bismuth displays a higher eradication rate than that of the classical bismuth quadruple therapy on the first-time elimination failure of Helicobacter pylori while shows no difference in safety consideration,thus can serve as remedial therapy for the primary Hp eradication failure.